Glycemic control and the risk of acute kidney injury in patients with type 2 diabetes and chronic kidney disease: parallel population-based cohort studies in U.S. and Swedish routine care
posted on 2020-10-06, 19:34authored byYang Xu, Aditya Surapaneni, Jim Alkas, Marie Evans, Jung-Im Shin, Elizabeth Selvin, Alex Chang, Morgan E Grams, Juan Jesus Carrero
<b>Objective:
</b>Patients
with diabetes and chronic kidney disease (CKD) have increased susceptibility to
acute kidney injury (AKI), but mechanisms are unclear. We investigated the
association of glycemic control with risk of AKI.
<p><b>Research
Design and Methods: </b>In two
observational cohorts of U.S. (Geisinger Heath system, Pennsylvania) and
Swedish (SCREAM project, Stockholm) adults with type-2 diabetes and confirmed
CKD stages G3-G5 undergoing routine care, we evaluated associations between
baseline and time-varying HbA1c with the incident AKI (defined as increase in creatinine
≥0.3 mg/dL over 48 hours, 1.5x creatinine over 7 days). </p>
<p><b>Results:
</b>In the U.S. cohort, there were
22877 patients (55% women) with median age 72 years and eGFR 52 ml/min/1.73 m<sup>2</sup>.
In the Swedish cohort, there were 12157 patients (51% women) with median age 76
years and eGFR 51 ml/min/1.73 m<sup>2</sup>. During 3.1 and 2.3 years of follow-up,
7060 and 2619 AKI events were recorded in the U.S. and Swedish cohorts,
respectively. The adjusted association between baseline HbA1c and AKI was
similar in both cohorts. Compared to baseline HbA1c 6-6.9% (42-52 mmol/mol), the
HR for AKI in patients with HbA1c>9% (75 mmol/mol) was 1.29 (95% CI 1.18-1.41)
in Geisinger, and 1.33 (95% CI 1.13-1.57) in the Swedish cohort. Results were
consistent in stratified analysis, when using death as competing risk, and when
using time-varying HbA1c.</p>
<p><b>Conclusions: </b>Higher HbA1c was associated with AKI in adults with type 2 diabetes and
CKD, suggesting that improving glycemic control may reduce the risk of AKI.</p>
Funding
Research reported in this publication was supported by the Swedish Research Council 2019-01059 (PI: Dr. Carrero), R01 DK115534 and R01 DK100446 (PI: Dr Grams), and K01 DK121825 (PI: Dr. Shin) from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. The funding sources had no role in the design and conduct of the study, analysis or interpretation of the data, and preparation or final approval of the manuscript before publication.